Correlation Between MIB1-Determined Tumor Growth Fraction and Incidence of Tumor Recurrence in Early Ovarian Carcinomas

References

• McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. Y., Clarke-Pearson D. L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996; 334: 1–6, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• du Bois A., Lück H. J., Meier W., Möbus V., Costa S., Richter B., Warm M., Bauknecht T., Schröder W., Olbricht S., Nitz U., Jackisch C. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. Semin. Oncol. 1997; 24(S15)44–52
   Google Scholar
• Eisenhauer E. A., Gore M., Neijt J. P. Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner?. Ann. Oncol. 1999; 10: 9–15, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• von Georgi R., Franke F. E., Münstedt K. The influence of tumorbiology, surgery, and postoperative therapy on patient prognosis in advanced ovarian carcinomas. Eur. T. Obstet. Gynecol. Reprod. Biol. 2003; 11: 189–196
   Google Scholar
• NIH Consensus Conference. Ovarian cancer: screening, treatment, and follow-up. J. Am. Med. Assoc. 1995; 6: 491–497
   Google Scholar
• Bolis G., Colombo N., Pecorelli S., Torri V., Marsoni S., Bonazzi C., Chiari S., Favalli G., Mangili G., Presti M., Zanaboni F., Mangioni C., GICOG. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann. Oncol. 1993; 6: 887–893
   Web of Science ®Google Scholar
• Young R. C., Walton L. A., Ellenberg S. S., Homesley H. D., Wilbanks G. D., Decker D. G., Miller A., Park R., Major F., Jr. Adjuvant therapy in stage I and stage II epithelial ovarian cancer—results of two prospective randomized trials. N. Engl. J. Med. 1990; 322: 1021–1027, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Deppe G., Baumann P. Advances in ovarian cancer chemotherapy. Curr. Opin. Oncol. 2000; 12: 481–491, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Brinkhuis M., Meijer G. A., Baak J. P.A. An evaluation of prognostic factors in advanced ovarian cancer Eur. J. Obstet. Gynecol. Reprod. Biol. 1995; 63: 115–124, [CSA]
   Google Scholar
• Tropé C. Prognostic factors in ovarian cancer. Cancer Treat. Res. 1998; 95: 287–352, [CSA]
   PubMedGoogle Scholar
• Trimble E. L., Kaern J., Tropé C. Management of borderline tumors of the ovary. Ovarian Cancer: Controversies in Management, D. M. Gershenson, W. P. McGuire. Churchill Livingston, New York 1998; 195–218
   Google Scholar
• Key G., Meggetto F., Becker M. H., al Saati T., Schluter C., Duchrow M., Delsol G., Gerdes J. Immunobiochemical characterization of the antigen detected by monoclonal antibody IND.64. Evidence that IND.64 reacts with the cell proliferation associated nuclear antigen previously defined by Ki-67. Virchows Arch., B. Cell Pathol. Incl. Mol. Pathol. 1992; 62: 259–262, [CSA]
   PubMedGoogle Scholar
• McCormick D., Chong H., Hobbs C., Datta C., Hall P. A. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology 1993; 22: 355–360, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sittel C., Eckel H. E., Damm M., von Pritzbuer E., Kvasnicka H. M. Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factor recurrence in T1 and T2 laryngeal carcinoma. Laryngoscope 2000; 110: 1012–1017, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wu T. T., Chen J. H., Lee Y. H., Huang J. K. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J. Urol. 2000; 163: 758–760, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Grabenbauer G. G., Mühlfriedel C., Rödel F., Niedobitek G., Hornung J., Rödel C., Martus P., Iro H., Kirchner T., Steininger H., Sauer R., Weidenbecher M., Distel L. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48: 1041–1050, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hoos A., Stojadinovic A., Mastorides S., Urist M. J., Polsky D., Di Como M. F., Cordon-Cardo C. High Ki-67 proliferative index predicts disease specific survival in patients with righ-risk soft tissue sarcomas. Cancer 2001; 92: 869–874, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Pinder S. E., Wencyk P., Sibbering D. M., Bell J. A., Elston C. W., Nicholson R., Robertson J. F., Blamey R. W., Ellis I. O. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br. J. Cancer 1995; 71: 146–149, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Rioux-Leclercq N., Turlin B., Bansard J., Patard J., Maunta A., Moulinoux J. P., Guille F., Ramee M. P., Lobel B. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000; 55: 501–505
   PubMed Web of Science ®Google Scholar
• Pfister C., Lacombe L., Vezina M. C., Moore L., Larue H., Tetu B., Meyer F., Fradet Y. Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. Human Pathol. 1999; 30: 1350–1355, [CSA]
   PubMed Web of Science ®Google Scholar
• Friedlander M., Leary J., Russel P. An evaluation of CA125, CA1 and peanut lectin immunoreactivity in epithelial ovarian neoplasms: correlation with histopathological features, prognostic variables and patient outcome. Pathology 1998; 20: 38–44
   Google Scholar
• Gasparini G., Bonoldi E., Viale G., Verderio P., Boracchi P., Panizzoni G. A., Radaelli U., Dibacco A., Guglielmi R. B., Bevilacqua P. Prognostic and predictive value of tumor angiogenesis in ovarian carcinomas. Int. J. Cancer 1996; 69: 205–211, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Münstedt K., Steen J., Knauf A. G., Buch T., von Georgi R., Franke F. E. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 2000; 89: 1783–1791
   PubMed Web of Science ®Google Scholar
• Austin R. M., Norris H. J. Malignant Brenner tumor and transitional cell carcinoma of the ovary: comparison. Int. J. Gynecol. Pathol. 1997; 6: 29–39
   Google Scholar
• Russell P., Farnsworth A. Surgical Pathology of the Ovaries2nd Ed. Churchill Livingston, New York 1997
   Google Scholar
• Silva E. G., Robey-Cafferty S. S., Smith T. L., Gershenson D. M. Ovarian carcinomas with transitional cell carcinoma pattern. Am. J. Clin. Pathol. 1990; 93: 457–465, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Baak J. P.A., Chan K. K., Stolk J. G., Kenemans P. Prognostic factors in borderline and invasive ovarian tumours of the common epithelial type. Pathol. Res. Pract. 1987; 182: 755–774, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Valverde J. J., Martin M., García-Asenjo J. A., Casado A., Vidart J. A., Díaz-Rubio E. Prognostic value of DNA quantification in early epithelial ovarian carcinoma. Obstet. Gynecol. 2001; 97: 409–416, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Remmele W., Schicketanz K. H. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol. Res. Pract. 1993; 189: 862–866, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Franke F. E., Pauls K., Kerkman L., Steger K., Klonisch T., Metzger R., Alhenc-Gelas F., Burkhardt E., Bergmann M., Danilov S. M. Somatic isoforms of angiotensin-I-converting enzyme in the pathology of testicular germ cell tumors. Human Pathol. 2000; 31: 1466–1476, [CSA]
   PubMed Web of Science ®Google Scholar
• Rubin S. C., Hoskins W. J., Saigo P. E., Chapman D., Hakes T. B., Markman M., Reichman B., Almadrones L., Lewis J. L. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol. Oncol. 1991; 42: 137–141, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Altavilla G., Marchetti M., Padovan P., Marcato E., Onnis A. Predictive value of proliferative cellular nuclear antigen (PCNA) and Ki-67 antigen in advanced stage serous papilliferous ovarian cancer. Eur. J. Gynaecol. Oncol. 1996; 17: 524–528, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kerns B.-J. M., Jordan P. A., Faerman L. L., Berchuck A., Bast R. C., Layfield L. J. Determination of proliferation index with MIB-1 in advanced ovarian cancer using image analysis. Am. J. Clin. Pathol. 1994; 101: 192–197, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Garzetti G. G., Ciavattini, Goteri G., De Nictolis M., Stramazotti D., Lucarini G., Biagini G. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol. Oncol. 1995; 56: 169–174, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Anttila M., Kosma V.-M., Ji H., Puolakka J., Juhola M., Saarikoski S., Syrjänen K. Clinical significance of α-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J. Clin. Oncol. 1998; 16: 2591–2600, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Viale G., Maisonneuve P., Bonoldi E., Di Bacco A., Bevilacqua P., Panizzoni G. A., Radaelli U., Gasparini G. The combined evaluation of p53 accumulation and of Ki-67 (MIB1)labeling index provides independent information on overall survival of ovarian carcinoma patients. Ann. Oncol. 1997; 8: 469–476, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sengupta P. S., McGown A. T., Bajaj V., Blackhall F., Swindall R., Bromley M., Shanks J. H., Ward T., Buckley C. H., Reynolds K., Slade R. J., Jayson G. C. p53 and related proteins in epithelial ovarian cancer. Eur. J. Cancer 2000; 36: 2317–2328, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Henriksen R., Strang P., Backstrom T., Wilander E., Tribukait B., Oberg K. Ki-67 immunostaining and DAN flow cytometry as prognostic factors in epithelial ovarian cancers. Anticancer Res. 1994; 14: 603–608, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Auer G., Einhron N., Nilsson B., Silfverswärd C., Sjövall K. Biological malignancy grading in early-stage ovarian carcinoma. Acta Oncol. 1996; 35(S8)93–98, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Sainz de la Cuesta R., Goff B. A., Fuller A. F., Jr., Nikrui N., Eichhorn J. H., Rice L. W. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet. Gynecol. 1994; 84: 1–7, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kodama S., Tanaka K., Tokunaga A., Sudo N., Takahashi T., Matsui K. Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II. Int. J. Gynecol. Obstet. 1997; 56: 147–153, [CSA]
   PubMed Web of Science ®Google Scholar
• Vergote I., De Brabanter J., Fyles A., Bertelsen K., Einhorn N., Sevelda P., Gore M. E., Kaern J., Verrelst H., Sjövall J., Timmerman D., Vandewalle J., Van Gramberen M., Tropé C. G. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357: 176–182, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Lehner R., Wenzl R., Heinzl H., Husslein P., Sevelda P. Influence of delayed staging laparotomy after laparoscopic removal of ovarian masses later found malignant. Obstet. Gynecol. 1998; 92: 967–971, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tropé C., Kaern J., Hogberg T., Abeler V., Hagen B., Kristensen G., Onsrud M., Pettersen E., Rosenberg P., Sandvei R., Sundflor K., Vergote I. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann. Oncol. 2000; 11: 281–288
   PubMed Web of Science ®Google Scholar
• Schueler J. A., Trimbos J. B., van der Burg M., Cornelisse C. J., Hermans J., Fleuren J. G. DNA index reflects the biological behavior of ovarian carcinoma stage I-IIa. Gynecol. Oncol. 1996; 62: 59–66, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ahmed F. Y., Wiltshaw E., A'Hern R. P., Nicol B., Shepherd J., Blake P., Fisher C., Gore M. E. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J. Clin. Oncol. 1996; 14: 2968–2975, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Vergote I. B., Vergote-De Vos L., Abeler V. M., Aas M., Lindegaard M. W., Kjorstad K. E., Tropé C. G. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992; 69: 741–749, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bichel P., Jakobsen A. A new histologic grading index in ovarian carcinoma. Int. J. Gynecol. Pathol. 1989; 8: 147–155, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Shimizu Y., Kamoi S., Amada S., Hasumi K., Akiyama F., Silverberg S. G. Toward the development of a universal grading system for ovarian epithelial carcinoma. Gynecol. Oncol. 1998; 70: 2–12, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Baak J. P.A., Langley F. A., Talerman A., Delemarre J. F.M. Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal. Quant. Cytol. Histol. 1986; 8: 354–357, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gilchrist K. W., Kalish T. H.C., Gould V. E., Hirschl S., Imbriglia J. E., Levy W. M., Patchefsky A. S., Penner D. W., Pickren J., Roth J. A., Schinella R. A., Schwartz I. S., Wheeler J. E. Interobserver reproducibility of histopathological features in stage II breast cancer: an EORTC study. Breast Cancer Res. Treat. 1985; 5: 3–10, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Marx D., Meden H., Brune T., Kron M., Korabiowska M., Kuhn W., Schauer A. Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Anticancer. Res. 1997; 17: 775–780, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar